Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer

Oncologist

Volumn 17, Issue 3, 2012, Pages 419-427

  Delate, Thomas ^a   Witt, Daniel M ^a   Ritzwoller, Debra ^a   Weeks, Jane C ^b   Kushi, Lawrence ^c   Hornbrook, Mark C ^d   Aiello Bowles, Erin J ^e   Schrag, Deborah ^b  

^a KAISER PERMANENTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DIVISION OF RESEARCH   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Ambulatory care; Anticoagulants; Neoplasms; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOSPITAL PATIENT; HUMAN; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTPATIENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SOLID TUMOR; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OUTPATIENTS; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84859388695     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0323     Document Type: Article

References (27)

1. Trousseau A. Phlegmasia alba dolens, Clinique medicale de l'Hotel-Dieu de Paris, 3. Paris: Balliere, 1865;654-712.
2. Lindblad B, Sternby N, Berquist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-711.
3. Lee AYY, Levine MN. The thrombophilic state induced by therapeutic agents in cancer patient. Semin Thromb Hemost 1999;25:137-145.
4. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
5. Kearon C, Kahn SR, Agnelli G et al.; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133: 454S-545S.
6. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S.
7. Lyman GH, Khorana AA, Falanga A et al.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
8. National Comprehensive Cancer Network. Practice Guidelines in Oncology-v. 1.2010: Venous thromboembolism disease. Available at http://www. nccn.org/professionals/physician_gls/pdf/vte.pdf, accessed March 15, 2011.
9. Akl EA, Vasireddi SR, Gunukula S et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011;6:CD006649.
10. McManus RJ, Fitzmaurice DA, Murray E et al. Thromboembolism. Clin Evid 2011;pii:0208.
11. Wittkowsky AK. Barriers to long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 2006; 4:2090-2091.
12. Imberti D, Agnelli G, Ageno W et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008;93: 273-278.
13. Hornbrook MC, Hart G, Ellis JL et al. Building a virtual cancer research organization. Available at http://crn.cancer.gov. J Natl Cancer Inst Monogr 2005;(35):12-25.
14. Zhan C, Battles J, Chiang YP et al. The validity of ICD-9-CM codes in identifying postoperative deep vein thrombosis and pulmonary embolism. Jt Comm J Qual Patient Saf 2007;33:326-331.
15. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43: 1130-1139.
16. Cohen AT, Tapson VF, Bergmann JF et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371:387-394.
17. Witt DM, Sadler MA, Shanahan RL et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:1515-1522.
18. Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000;26(suppl 1):69-77.
19. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
20. Masci G, Magagnoli M, Zucali PA et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003;21:736-739.
21. Hill R, Martinez K, Delate T et al. A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services. J Thromb Thrombolysis 2009;27:334-337.
22. Noble SI, Nelson A, Turner C et al. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 2006;332:577-580.
23. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park) 2003;17:126-135, 139; discussion 139-144.
24. Prandoni P, Lensing AW, Prins MH et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960.
25. Kuijer PMM, Hutten BA, Prins MH et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457-460.
26. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298-310.
27. Tagalakis V, Kahn SR. Determining the test characteristics of claims-based diagnostic codes for the diagnosis of venous thromboembolism in a medical service claims database. Pharmacoepidemiol Drug Saf 2011;20:304-307.